Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q1 EPS of ($0.57), $0.07 worse than the analyst estimate of ($0.50).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.